# SoniVie

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/sonivie

- Industry: Medical Devices & Equipment
- Headquarters: Rehovot, Israel
- Website: www.sonivie.com
- Total disclosed funding: $60M
- Latest round: Series C (Jan 9, 2023)
- Investors on record: 4

## About

Based in Rehovot, Israel, and founded in 2014, SoniVie Ltd. operates as a medical device company. In January 2023, SoniVie Inc. raised USD 60 million in Series C funding led by Andera Partners, Omega Funds, Supernova Invest, and Techwald Holding. As of 2022, the company’s CEO is Tomaso Zambelli. SoniVie provides TIVUS (therapeutic intra-vascular ultrasound system), which is a medical device that works on catheter-based technology that was developed for the treatment of pulmonary artery hypertension (PAH). People with chronic obstructive pulmonary disease (COPD) and patients with resistant hypertension are among the groups of patients who utilize the company’s medical device. The company plans to use the funds raised in January 2023 to support its development and its program called TIVUS renal artery denervation.

## Funding rounds

- Series C, Jan 9, 2023, $60M — Andera Partners, Omega Funds, Supernova Invest, Techwald Holding

## Investors

- Andera Partners (https://capitalatlas.ai/funds/andera-partners) — Series C
- Omega Funds (https://capitalatlas.ai/funds/omega-funds) — Series C
- Supernova Invest (https://capitalatlas.ai/funds/supernova-invest) — Series C
- Techwald Holding (https://capitalatlas.ai/funds/techwald-holding) — Series C